Want to see SCNI full AI Analyst Report?
SCNI Stock Chart & Stats
$0.23
-$0.02(-6.92%)
At close: 4:00 PM EDT
$0.23
-$0.02(-6.92%)
Day’s Range― - ―
52-Week Range$0.21 - $1.97
Previous CloseN/A
Volume35.26K
Average Volume (3M)101.31K
Market Cap
$1.09M
Enterprise Value$8.17
Total Cash (Recent Filing)$3.11M
Total Debt (Recent Filing)$3.50M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3837.20
Shares Outstanding3,959,792
10 Day Avg. Volume127,573
30 Day Avg. Volume101,310
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)1.27
P/FCF Ratio-0.27
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CDMO Capability ExpansionAcquiring Recipharm Israel and consolidating CDMO activities builds tangible manufacturing scale and technical capability. This diversifies revenue toward fee-for-service work, supports commercialization pathways for biologics, and creates a repeatable, asset-backed revenue stream that can persist beyond short-term market cycles.
Improved Balance Sheet CapitalizationMaterially stronger equity and manageable leverage reduce solvency risk versus prior years and increase financial flexibility. That improvement supports investment in CDMO scale-up and clinical programs without immediate distress, making external funding or borrowing less acutely constrained over the medium term.
Early Revenue TractionConsistent revenue growth from near-zero levels demonstrates initial commercial adoption and CDMO contribution (including Yavne). While small, this trend shows the company moving from pure research funding toward operating revenue, a structural step that can underpin future margin improvement if scaled.
Bears Say
Persistent Negative Cash FlowSustained negative operating cash flow indicates ongoing cash burn to fund R&D and expanded operations. Over the medium term this necessitates external financing or material revenue growth; otherwise it risks dilution, constrained investment in clinical milestones, or curtailed CDMO ramp-up if funding proves limited.
Negative Gross Profit And Large Operating LossesNegative gross profit and deeply negative operating margins show the cost base is still development-heavy and not covered by sales. Structurally, this prevents sustainable profitability until either revenues scale substantially or cost structure is re-aligned, leaving long-term earnings quality weak.
Acquired Subsidiary Financial WeaknessIntegrating a loss-making subsidiary with working capital and equity deficits creates near-term funding and operational risk. The parent may need to provide ongoing support, which can offset the acquisition's strategic benefits and strain consolidated cash flow and management focus over the medium term.
Scinai Immunotherapeutics News
SCNI FAQ
What was Scinai Immunotherapeutics’s price range in the past 12 months?
Scinai Immunotherapeutics lowest stock price was $0.21 and its highest was $1.97 in the past 12 months.
What is Scinai Immunotherapeutics’s market cap?
Scinai Immunotherapeutics’s market cap is $1.09M.
When is Scinai Immunotherapeutics’s upcoming earnings report date?
Scinai Immunotherapeutics’s upcoming earnings report date is Aug 20, 2026 which is in 18 days.
How were Scinai Immunotherapeutics’s earnings last quarter?
Scinai Immunotherapeutics released its earnings results on Jun 10, 2026. The company reported $0 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Scinai Immunotherapeutics overvalued?
According to Wall Street analysts Scinai Immunotherapeutics’s price is currently Overvalued.
Does Scinai Immunotherapeutics pay dividends?
Scinai Immunotherapeutics does not currently pay dividends.
What is Scinai Immunotherapeutics’s EPS estimate?
Scinai Immunotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics has 3,959,792 shares outstanding.
What happened to Scinai Immunotherapeutics’s price movement after its last earnings report?
Scinai Immunotherapeutics reported an EPS of $0 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.627%.
Which hedge fund is a major shareholder of Scinai Immunotherapeutics?
Currently, no hedge funds are holding shares in SCNI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Technical Analysis
Ownership Overview
― Insiders
―
Mutual Funds
0.37% Other Institutional Investors
99.63% Public Companies and
Individual Investors